Three recent meta-analyses demonstrated that oral administration of propranolol to newborns with ROP slows down the progression of retinal neovascularization and reduces the indication for laser photocoagulation or anti-VEGF drugs (Kaempfen et al., 2018; Stritzke al., 2019; Kong et al., 2021). This evidence concerns the gene VEGFA and retinopathy of prematurity.